Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum

  • days left to enroll
  • participants needed
  • sponsor
    InflaRx GmbH
Updated on 25 April 2021


The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of pyoderma gangrenosum.


Neutrophilic dermatoses are a spectrum of inflammatory disorders characterized by skin lesions resulting from a neutrophil-rich inflammatory infiltrate in the absence of infection. Pyoderma gangrenosum is associated with a neutrophilic leukocytosis, which is likely to be triggered by C5a. This study is set up based on the hypothesis that IFX-1 might be able to block C5a induced pro-inflammatory effects such as neutrophil activation and cytokine generation, potentially contributing to the local skin inflammation and tissue damage.

Condition Pyoderma Gangrenosum
Treatment IFX-1
Clinical Study IdentifierNCT03971643
SponsorInflaRx GmbH
Last Modified on25 April 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of an ulcerative form of pyoderma gangrenosum confirmed by the investigator
In addition, the subject must fulfill at least 3 of the following 6 criteria
at screening
History of
Pathergy (ulcer occurring at the sites of trauma)
Personal history of inflammatory bowel disease or inflammatory arthritis
History of papule, pustule or vesicle that rapidly ulcerated
Clinical examination (or photographic evidence) of
Peripheral erythema, undermining border, and tenderness at site of ulceration
Multiple ulcerations (at least 1 occurring on the lower leg)
Cribriform or "wrinkled paper" scar(s) at sites of healed ulcers
Subject has a minimum of 1 evaluable ulcer (2 cm2) on the lower extremity at

Exclusion Criteria

Pyoderma gangrenosum target ulcer for more than 3 years before screening
Surgical wound debridement within the previous 2 weeks before screening
Use of intravenous antibacterials, antivirals, anti-fungals, or anti-parasitic agents within 30 days before screening
Any drug treatment for pyoderma gangrenosum including corticosteroids (>10 mg), intralesional steroids, cyclosporine A, biologicals and immunosuppressives (with the exception of antibiotics for wound superinfection) used within a time of 5 half-lives of the drug before screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note